TRAILBLAZER-ALZ 2 is a Phase 3, double-blind, placebo-controlled study to evaluate the safety and efficacy of N3pG antibody (donanemab) in participants with early symptomatic AD (prodromal AD and mild dementia due to AD) with the presence of brain tau pathology.~Following the double-blind 76-week main study period, a double-blind 78-week long-term extension period is added to further evaluate donanemab efficacy and safety over time. Participants from the addendum safety cohort are not eligible for the extension period.
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.~Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab.